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The rising prevalence and burden of depression worldwide 
disproportionately affect low- and middle-income countries.1–4 
Major depressive and bipolar disorders independently increase 
the risk for other chronic diseases, including cardiovascular 
disease, metabolic syndrome and obesity.5,6 Higher rates of 
multimorbidity and poorer physical health outcomes are 
observed among individuals with mental disorders, relative 
to those without mental disorders; these factors contribute 
excess morbidity and mortality among individuals with de-
pression, particularly in low- and middle-income countries.7–12 
Objective To evaluate the development and implementation of clinical practice guidelines for the management of depression globally.
Methods We conducted a systematic review of existing guidelines for the management of depression in adults with major depressive or 
bipolar disorder. For each identified guideline, we assessed compliance with measures of guideline development quality (such as transparency 
in guideline development processes and funding, multidisciplinary author group composition, systematic review of comparative efficacy 
research) and implementation (such as quality indicators). We compared guidelines from low- and middle-income countries with those 
from high-income countries.
Findings We identified 82 national and 13 international clinical practice guidelines from 83 countries in 27 languages. Guideline development 
processes and funding sources were explicitly specified in a smaller proportion of guidelines from low- and middle-income countries 
(8/29; 28%) relative to high-income countries (35/58; 60%). Fewer guidelines (2/29; 7%) from low- and middle-income countries, relative 
to high-income countries (22/58; 38%), were authored by a multidisciplinary development group. A systematic review of comparative 
effectiveness was conducted in 31% (9/29) of low- and middle-income country guidelines versus 71% (41/58) of high-income country 
guidelines. Only 10% (3/29) of low- and middle-income country and 19% (11/58) of high-income country guidelines described plans to 
assess quality indicators or recommendation adherence.
Conclusion Globally, guideline implementation is inadequately planned, reported and measured. Narrowing disparities in the development 
and implementation of guidelines in low- and middle-income countries is a priority. Future guidelines should present strategies to implement 
recommendations and measure feasibility, cost–effectiveness and impact on health outcomes.
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Furthermore, the growing awareness of 
the social determinants of mental disor-
ders provides the impetus to prioritize 
the development and implementation 
of evidence-based practices for depres-
sion management in low- and middle-
income countries. 
Clinical practice guidelines trans-
late research into recommendations 
to standardize care, improve health 
outcomes and reduce morbidity and 
mortality.13,14 We conducted a systematic 
review of existing guidelines for the 
management of depression in adults 
with major depressive or bipolar disor-
der. We compared guidelines from low-, 
middle- and high-income countries to 
characterize disparities in the develop-
ment and implementation of guidelines 
globally.
Methods
We conducted a systematic review 
concordant with Preferred Report-
ing Items for Systematic Reviews and 
Meta-Analyses recommendations.15 Our 
protocol was registered in the Interna-
tional Prospective Register of Systematic 
Reviews (CRD42019124759).16
Search strategy
We searched the following online data-
bases from 1994 to January 2019, without 
language restrictions: Ovid®, MEDLINE® 
PubMed®, Embase®, ProQuest PsycIN-
FO®; Web of Science, KCI-Korean Jour-
nal, Russian Science Citation Index, and 
SciELO Citation Index; African Journals 
Online; PakMediNet; EBSCO CINAHL 
Plus; and Cochrane Library. We searched 
titles and abstracts using medical search 
heading terms and keywords. Text key-
words used include, for example: bipolar 
disorder, depressive disorder, mood 
disorders, depressi*, practice guidelines, 
evidence-based medicine, guideline*, 
(medical OR psychiatric association) 
AND (treatment OR management OR 
clinical recommendation*). The full 
search records and details of the grey 
literature and manual searches are avail-
able in the data repository.17
Inclusion and exclusion criteria
We included national and international 
guidelines for the management of de-
pression in adults (aged approximately 
18–70 years) with major depressive or 
bipolar disorder defined by standardized 
diagnostic criteria. Diagnostic criteria 
included the International statistical 
classification of diseases and related 
health problems, 10th edition (ICD-10) 
and the Diagnostic and statistical manual 
of mental disorders (DSM-IV, DSM-IV-
TR and DSM-5). We excluded guidelines 
published exclusively for the treatment 
of depressive symptoms in the absence 
of major depressive or bipolar disorder; 
developed for use in local regions, hos-
pitals, states or provinces; developed 
before 1994 (based on, for example, 
ICD-9 or DSM-III); or with inaccessible 
full-texts (we approached authors for ac-
cess to full-text publications of relevant 
guidelines). Guidelines with original 
and updated recommendations were 
considered duplicates (the most recent 
update was reviewed). Additional selec-
tion and data extraction processes are 
available in the data repository.17
Quality assessment
We evaluated the quality of the guide-
line development process by assess-
ing compliance to the Institute of 
Medicine’s eight standards for clinical 
practice guidelines: (i) transparency 
in guideline development processes 
and funding; (ii) disclosure, manage-
ment and divestment of conflicts of 
interest; (iii) multidisciplinary and 
balanced composition of development 
group; (iv) recommendations based 
on a systematic review; (v) rating of 
evidence quality and strength of recom-
mendation grading; (vi) articulation of 
recommendations; (vii) external review 
process; and (viii) schedule for guideline 
update.14 A guideline was externally 
reviewed if it was made available to the 
general public or target users and rel-
evant stakeholders for comment before 
its publication. A guideline develop-
ment group was multidisciplinary and 
balanced if it included subject-matter 
experts, clinicians and patient represen-
tatives. A guideline met the standard for 
strength of recommendation grading if 
all of the following were included for at 
least three quarters of its recommenda-
tions: evidence, harms, benefits, and 
level of confidence. A guideline clearly 
articulated its recommendations if each 
stated recommendation was specific, 
unambiguous and actionable. 
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We adopted measures from the 
GuideLine Implementability Appraisal 
and other published criteria to evaluate 
how amenable each guideline was to 
implementation.18,19 We assessed char-
acteristics of the guideline development 
process that facilitate the adoption and 
application of guideline recommenda-
tions: attention to ease of implementa-
tion; consideration of economic, legal, 
social and ethical issues; appraisal of 
economic or resource implications; eval-
uation of patient preferences; assessment 
of implementation enablers and barri-
ers; credibility of authoring individuals 
or organizations; and the provision of 
tools to facilitate guideline adoption. 
We assessed a guideline as having con-
sidered the ease of implementation if 
recommendations requiring minimal 
resources were presented before those 
requiring more intensive resources. Less 
intensive interventions were, for exam-
ple, those with minimal need for highly 
skilled personnel, medications, and 
expensive facilities or infrastructure.18 
We determined the individuals or orga-
nizations who authored the guidelines as 
having credibility if their expertise was 
concordant with the target audience (for 
example, a psychiatric association had 
published recommendations intended 
for psychiatrists).
The data extraction form is available 
in the data repository.17
Critical appraisal
We compared outcome measures be-
tween guidelines from high-, upper-mid-
dle- and low- or lower-middle-income 
countries, as classified by the World Bank 
for the fiscal year of the publication date.20 
We pooled guidelines from low- and 
lower-middle-income countries for the 
analysis as there was only one national 
guideline from a low-income country. 
Other low-income countries without 
national guidelines had guidelines as part 
of international guidelines. We excluded 
international guidelines from compari-
sons between income classifications,21–28 
unless they were developed for countries 
uniformly belonging to a single income 
classification.29–33 
We evaluated to what extent dif-
ferences in access to quality health 
care predict disparities in the quality of 
guideline development processes ob-
served across income classifications. The 
median Healthcare Access and Quality 
index was computed for each income 
classification group using the most re-
cently published index estimates.34 The 
global Healthcare Access and Quality 
index was 54.4 in 2016; higher indices 
indicate greater access to quality health 
care (range: 0–100).34
We present numbers and percent-
ages of total number of guidelines across 
or within income groups, as relevant. 
We conducted statistical analyses using 
R software version 3.4.4 (R Founda-
tion for Statistical Computing, Vienna, 
Austria), with α = 0.05.35 We compared 
outcomes between income classifica-
tions using glm for logistic regressions. 
We computed incident rate ratios (IRRs) 
using msm::deltamethod and robust 
(White–Huber) standard errors (SE) 
using sandwich::vcovHC to evaluate the 
association between Healthcare Access 
and Quality index and guideline devel-
opment quality. 
Results
Our database searches yielded 9833 
records. After screening the titles and 
abstracts of non-duplicate records, we 
reviewed the full texts of 312 records for 
eligibility (Fig. 1). A total of 95 guide-
lines from 83 countries met our inclu-
sion criteria (Table 1; available at: http:// 
www .who .int/ bulletin/ volumes/ 98/ 10/ 
20 -251405). Fig. 2 (available at: http:// 
www .who .int/ bulletin/ volumes/ 98/ 
10/ 20 -251405) illustrates all countries 
with at least one depression guideline; 
the countries are grouped by income 
classification. There were 82 national 
guidelines36–124 and 13 international 
guidelines. 
Of the 13 international guidelines, 
five were from countries in the same 
income group.29–33 Of the eight guide-
lines from countries in different income 
groups, five covered low- or lower-
middle income countries that lacked 
national guidelines.21–24,28 However, only 
two international guidelines included at 
least one author from a low- or lower-
middle-income country.21,22 Guidelines 
were published in 27 languages, pre-
dominantly in the English language (40 
guidelines; 42%).
Target populations and users
Fifty-two guidelines were specifically 
developed for major depressive dis-
order and 33 for bipolar disorder. 
One guideline was developed for the 
treatment of mood disorders, four for 
psychiatric disorders, one for psychi-
atric and neurological disorders, one 
for medical and psychiatric disorders, 
and three for depression in special 
populations (perinatal depression, 
major depressive disorder with chronic 
Fig. 1. Flowchart of the systematic review of guidelines for management of depression
9833 records identified 
through database searches
220 records identified through 
manual searches
7276 records screened after 
duplicates removed
312 full-text articles assessed 
for eligibility
95 guidelines included in 
qualitative synthesis 
6964 records excluded after 
title and abstract review
217 full-text articles excluded for the 
following reasons:
• 129 not a practice guideline
• 57 duplicates 
• 12 target population did not have major 
depressive disorder or bipolar disorder
• 10 developed for local regions, hospitals, 
states, or provinces within a country
• 4 target population exclusively paediatric 
or geriatric
• 4 full-text not available
• 1 developed before 1994
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pain). Guidelines most often targeted 
psychiatrists (77 guidelines; 81%) and 
primary care providers (65 guidelines; 
68%). Only 19 (20%) and 13 (14%) of 
guidelines targeted policy-makers and 
payers (companies or organizations that 
finance the provision of health services), 
respectively (Table 2).
Scope and intent
The majority of guidelines recommend-
ed the use of the two-item Patient Health 
Questionnaire125 to screen for depressive 
symptoms. Fifty-seven guidelines (60%) 
provided recommendations related to 
depression screening, 51 of which sup-
ported screening for depression in the 
target setting (such as primary care), 
either systematically or selectively (such 
as in high-risk populations, postpartum 
women or settings with resources avail-
able for managing depression). The ma-
jority of these guidelines recommended 
the use of the two-item Patient Health 
Questionnaire125 to screen for depressive 
symptoms. Six guidelines recommended 
against screening for depression, cit-
ing insufficient evidence supporting 
its effectiveness. Most guidelines with 
screening recommendations were 
developed in high- or upper-middle-
income countries (53/57 guidelines). 
The majority of guidelines included rec-
ommendations for screening, measuring 
or treating cardiovascular and metabolic 
comorbidities (58 guidelines; 61%) or 
psychiatric comorbidities (65 guidelines; 
68%; Table 2).
Recommendations for the primary 
prevention of depression were included 
in 16 guidelines (17%), most of which 
were developed in high-income (10 
guidelines) or upper-middle-income 
countries (four guidelines). These guide-
lines described risk factors, strategies for 
reducing risk (such as lifestyle modifica-
tion, managing stress, psychoeducation 
or psychosocial support) and methods 
for early detection. Few guidelines 
evaluated the literature on the effec-
tiveness of different interventions for 
primary prevention or cited limitations 
of current evidence.
Fifteen guidelines (16%) provided 
decision support or recommendations 
for assessing work ability, sick leave 
or return to work; all were published 
by high-income or upper-middle-
income countries (Table 2). Eleven 
of these guidelines originated in Eu-
rope,42,58,59,65,92,114,120 while four of these 
guidelines originated in Canada, Chile, 
Colombia and Japan.66,68,102,103,115,117,119,126 
The recommendations were often lim-
ited to the discussion of standardized 
scales for measuring work-related im-
pairment, factors moderating patients’ 
return to work, resources for supporting 
patient employment or occupational 
rehabilitation and regional disability 
legislations. The guidelines from Colom-
bia, Finland, Netherlands and Sweden 
recommended that patients continue 
to work, unless otherwise indicated, 
and advised patients and clinicians to 
discuss work-related factors that may 
hinder recovery.66,92,102,103,114,115 Notably, 
the Swedish bipolar disorder guideline 
listed an employment rate of 50% among 
patients as a national target.122
Development processes
The quality of the guideline development 
processes varied across country income 
classifications. The median number of 
standards met was five (interquartile 
range: 3–7) for high-income country 
guidelines, two (interquartile range: 
1–4) for upper-middle-income country 
guidelines and one (interquartile range: 
0–1.5) for low- or lower-middle-income 
country guidelines. The World Health 
Organization (WHO) guidelines, de-
veloped specifically for low- and lower-
middle-income countries,21 met all 
but one Institute of Medicine-defined 
standard (systematic review of cost–ef-
fectiveness). 
Sixty-eight guidelines (72%) pro-
vided specific, unambiguous and action-
able recommendations, representing 
44 of 58 (76%), 13 of 22 (59%) and 
three of seven (43%) of guidelines from 
high-, upper-middle- and low- or lower-
middle-income countries, respectively 
(Fig. 3).
The guideline development process-
es and funding sources were explicitly 
specified in 51 guidelines (54%), only 
two of which originated in low- or low-
er-middle-income countries. Potential 
conflicts of interest were openly declared 
and managed in a higher proportion 
of guidelines from high-income (36 
guidelines; 62%) versus upper-middle-
income (six guidelines; 27%) and low- or 
lower-middle-income countries (two 
guidelines; 29%).
Only 25 guidelines (26%) were 
developed by a multidisciplinary group 
Table 2. Target audience and scope of guidelines for the management of depression, by 
country-level income classification 









Psychiatrists 52 (90) 15 (68) 6 (86) 4 (50)
Primary care providers 43 (74) 13 (59) 3 (43) 6 (75)
Other specialists 34 (59) 11 (50) 2 (29) 2 (25)
Psychologists 32 (55) 11 (50) 2 (29) 0 (0)
Nurses 31 (53) 9 (41) 2 (29) 1 (13)
Patients 19 (33) 0 (0) 1 (14) 0 (0)
Policy-makers 14 (24) 2 (9) 1 (14) 2 (25)
Payers 9 (16) 3 (14) 1 (14) 0 (0)
Scope and intent
Comorbidities
    Psychiatric 41 (71) 14 (64) 5 (71) 5 (63) 
    Cardiometabolic 41 (71) 11 (50) 4 (57) 2 (25)
Screeninga 36 (62) 17 (77) 4 (57) 0 (0)
Primary prevention 10 (17) 4 (18) 2 (29) 0 (0)
Work-related decision 
support
14 (24) 1 (5) 0 (0) 0 (0)
a  The majority of guidelines recommended the use of two diagnostic questions to screen for depressive 
symptoms: “During the past two weeks, have you often been bothered by little interest or pleasure in 
doing things” and “During the past two weeks, have you often been bothered by feeling down, depressed 
or hopeless.”125
Notes: Country income groups are World Bank classifications.20 International guidelines are from countries 
in different income groups. Total number of guidelines included: high-income countries: 58; upper-middle-
income countries: 22; low- or lower-income countries: 7; international (different income groups): 8.
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comprising subject experts, clinicians 
and patients or patient advocates. Devel-
opment groups often lacked patient or 
patient advocacy representation. None 
of the low- or lower-middle-income 
country guidelines had a multidisci-
plinary development group.
A systematic review of compara-
tive effectiveness of interventions being 
recommended had been carried out by 
57 guidelines (60%), all of which were 
developed by international authorship 
groups or in high- or upper-middle-
income countries. Some guidelines from 
low- or middle-income countries were 
based on recommendations of other 
published international guidelines. Only 
10 guidelines (11%), all from high- and 
upper-middle-income countries, had 
conducted a systematic review of cost–ef-
fectiveness of a particular intervention 
or set of recommendations. 
Forty guidelines (42%) included 
with their recommendations ratings of 
evidence, harms, benefits, and confi-
dence level. More guidelines from high-
income countries (27 guidelines; 47%) 
met the Institute of Medicine’s standard 
for strength of recommendation grad-
ing. Thirty-five guidelines (37%) had 
been externally reviewed (for example, 
by being posted for public comment or 
reviewed by stakeholders external to 
the development group); none of these 
guidelines originated in low- or lower-
middle-income countries.
Thirty-eight guidelines (40%) stated 
plans to renew or update their recom-
mendations, excluding three guidelines 
that were withdrawn past the scheduled 
updating date.36,54,78 Fewer guidelines 
provided a scheduled date for renewal 
(26 guidelines; 27%). The scheduled 
renewal date of these guidelines was 
often within 3–5 years of the publica-
tion date (mean: 4 years; standard 
deviation; SD: 2). Notwithstanding, 
49 guidelines (52%) were revisions, of 
which 17 guidelines were published 
within 5 years of the previous iteration. 
On average, guidelines were revised 
within 7 years (SD: 3). How frequently 
and how recently revisions were pub-
lished were similar between high- and 
middle-income countries (Fig. 3). None 
of the guidelines from low- or lower-
middle-income countries stated plans 
to revise recommendations or included 
a renewal date.
The median Healthcare Access and 
Quality index was significantly greater 
among guidelines from high-income 
Fig. 3. Quality of development process of guidelines for management of depression by 
country income classification
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% of guidelines
Notes: Country income groups are World Bank classifications.20 Quality of guideline development 
processes were appraised by measuring compliance to the Institute of Medicine-defined standards for 
clinical practice guidelines.14 
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Notes: Country income groups are World Bank classifications.20 y-axis is the median number of Institute of Medicine-defined 
standards met by guidelines within each income classification group. The dotted line indicates the global Healthcare Access 
and Quality index of 54.4 in 2016.34
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countries (median: 90.6; interquartile 
range: 88.8–94.0) relative to those from 
upper-middle-countries (median: 68.5; 
interquartile range: 66.3–77.9) and 
low- or lower-middle-income coun-
tries (median: 51.2; interquartile range: 
41.2–61.7; χ2 = 156.2, degrees of free-
dom = 72; P < 0.001; Fig. 4). Guidelines 
from countries with higher Healthcare 
Access and Quality indices met more 
Institute of Medicine-defined standards 
(IRR: 1.03; robust SE: 0.006).
Facilitators and barriers of 
implementation
The target patient population and in-
tended users were clearly defined in 
93 (98%) and 79 (83%) guidelines, re-
spectively. The authors of 75 guidelines 
(79%) met criteria for credibility with 
the intended audience (Fig. 5). Most 
of these guidelines originated in high-
income countries (52 guidelines).
Target users or patient representa-
tives evaluated enablers and barriers 
to the implementation of 24 guidelines 
(25%); 11 guidelines involved both tar-
get users and patient representatives, 11 
guidelines involved target users without 
patient representatives and two guide-
lines involved only patient representa-
tives in the evaluation of enablers and 
barriers. None of the guidelines from 
low- or lower-middle-income coun-
tries evaluated enablers and barriers to 
implementation.
Twenty-one guidelines (22%) evalu-
ated patient preferences by conducting 
literature reviews of patient preferences 
or by including patient representatives 
in the guideline development group, 
as external reviewers or as members of 
focus groups. None of the low- or lower-
middle-income country guidelines 
evaluated patient preferences.
Twenty-four guidelines (25%) or-
dered their recommendations by ease 
of use (for example, using a stepped-
care model). For management of mild 
depression, these guidelines recom-
mended low-intensity psychosocial 
and psychological interventions (for 
example, physical activity, psychoeduca-
tion, sleep modification or computerized 
cognitive behavioural therapy) before 
pharmacological interventions (for 
example, selective serotonin reuptake 
inhibitors) or high-intensity psychologi-
cal interventions (for example, cognitive 
behavioural therapy or interpersonal 
psychotherapy). Whether a guideline 
had ordered recommendations by ease 
of use varied across income classifica-
tions.
Eighteen guidelines (19%), mostly 
from high-income countries (15 guide-
lines), evaluated the resource implica-
tions of implementing guideline recom-
mendations. Five guidelines described 
personnel, infrastructure and training 
requirements for each recommenda-
tion in detail.21,41,66,80,114 Costs and other 
economic considerations informed the 
development of 29 guidelines (30%), 24 
of which were from high-income coun-
tries. Several European guidelines con-
ducted modelling analyses to project the 
cost–effectiveness and budget impact of 
their recommendations.41,80,102,114,115,119
The number of guidelines that 
considered legal or ethical issues did 
not vary across income classifications. 
Twenty-five guidelines (26%) discussed 
various legal aspects of patient care, such 
as involuntary treatment of psychiatric 
patients, certification requirements for 
professionals providing psychotherapy, 
availability of antidepressants across na-
tional regulatory agencies, national work 
or disability legislations and statutory 
patient rights. Twenty-one guidelines 
(22%) discussed ethical considerations 
relevant to care provision, such as risks 
versus benefits of taking medications 
while pregnant or breastfeeding and ob-
taining informed patient consent before 
initiating electroconvulsive therapy or 
off-label drug usage.
Thirty-nine guidelines (41%) dis-
cussed social aspects affecting patient 
care or illness presentation, such as race 
or ethnicity, and advised clinicians to 
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Notes: Country income groups are World Bank classifications.20 The numerator is given above each bar. International guidelines are from countries in different 
income groups. We adopted measures from the GuideLine Implementability Appraisal and other published criteria to evaluate how amenable each guideline was 
to implementation.18,19
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consider patient factors, such as social 
support availability, interpersonal re-
lationship quality, workplace or other 
factors influencing recovery, childhood 
trauma and developmental disabilities. 
Other guidelines, for example, empha-
sized the importance of adapting guide-
lines to local contexts and training end-
users to be culturally sensitive. Some 
guidelines commented on the lack of 
availability of personnel with sufficient 
training in some areas of the country 
and the implications of this for clinical 
care. More guidelines from high-income 
countries (29 guidelines; 50%) were 
informed by social considerations when 
compared to upper-middle-income 
(seven guidelines; 32%) and low- or 
lower-middle-income (none) countries.
Monitoring implementation
Thirty-three guidelines (35%), mostly 
from high-income countries (25 guide-
lines), operationalized monitoring 
or auditing criteria for assessing the 
implementation of guidelines. These 
guidelines suggested quality indicators 
or measures of guideline concordance, 
such as the proportion of patients pre-
scribed lithium or a selective serotonin 
reuptake inhibitor for at least four 
weeks.
Fifteen guidelines (16%), none of 
which were from low- or lower-middle 
income countries, described plans for 
assessing implementation of guidelines 
or adherence to guideline recommenda-
tions (Fig. 4). However, none of these 
guidelines provided plans to assess 
whether these actions would improve 
health or functional outcomes or cost–ef-
fectiveness. 
Guidelines described, for example, 
available health administrative data sets 
or national electronic medical records 
that could be used to assess measures 
of guideline implementation and qual-
ity indicators. The Swedish National 
Quality Register for Bipolar Disorder in-
cluded longitudinal data from 244 active 
health-care providers and approximately 
30% of patients with bipolar disorder in 
Sweden.127 Quality indicators included 
the percentages of patients diagnosed 
with a structured diagnostic instru-
ment, receiving psychoeducation, cur-
rently employed or who relapsed with a 
recurrent mood episode in 12 months, 
as well as sex and regional differences 
in lithium prescription.127 The National 
Institute for Health and Care Excellence 
in England measured the adoption of 
some recommendations across mental 
health guidelines, such as the proportion 
of people with subthreshold or mild-
to-moderate depression receiving low-
intensity psychosocial interventions.41 
WHO described the adoption of the 
Mental Health Gap Action Programme 
in 18 Member States, with a focus on 
informing future implementation plans 
and characterizing implementation en-
ablers and barriers.128
Sixty-five guidelines (68%) pro-
vided tools for guideline application, 
such as a quick reference summary. 
More high-income country (47/58) and 
international (6/8) guidelines provided 
implementation tools. Twenty-four 
guidelines (25%) described plans for 
disseminating guidelines, 29 of which 
originated in high-income countries.
Discussion
We found that many low- and lower-
middle-income countries, especially 
in Africa, lacked published clinical 
practice guidelines for the management 
of depression. However, international 
guidelines exist that cover or specifically 
target these countries.21–24,28 
While the overarching aim of 
guidelines is to improve health outcomes 
and cost–effectiveness, it remains un-
clear to what extent guidelines for the 
management of depression are being 
implemented and improving health 
outcomes, particularly in low- and 
lower-middle-income countries.128 Most 
guidelines lacked plans to assess quality 
indicators or recommendation imple-
mentation. We were unable to identify 
any national guidelines that included 
government-sanctioned incentives, 
such as remuneration, for adhering to 
guideline recommendations or penalties 
for not implementing recommendations 
at point-of-care. A notable exception, 
not included in the present review, is a 
guideline for adults with mood disorders 
from Florida, United States of Ameri-
ca.129 The guideline is integrated into an 
e-health infrastructure and mandated 
to be implemented with practitioner 
concordance monitoring. Government 
policies that require health-care pro-
viders to adhere to recommendations, 
via health insurance disbursement for 
example, may facilitate the implemen-
tation of guidelines and monitoring of 
effectiveness.
The disparities in availability, de-
velopment processes and quality of 
guidelines underscore an unmet need 
for decision support in low- and middle-
income countries.1,130 Due to limitations 
in access to resources, health-care 
personnel in low- and middle-income 
countries are additionally constrained 
in their ability to provide timely and 
appropriate patient care.34,131,132 Barriers 
to the application of standard interven-
tions in many low-resource settings 
include limitations in the availability 
of interventions (for example, regula-
tory approval of certain medicines or 
acquisition costs) and patient access to 
health-care professionals (for example, 
specialist fees, rural regions and private 
versus public clinics). Limitations in the 
availability of facilities and resources 
to monitor serum drug levels and liver 
or renal function (for example, with 
lithium treatment) may further limit 
access to treatments in low-resource 
settings.18,131–135 Recommendations 
to implement guidelines must be suf-
ficiently contextualized with relevant 
ethical, legal, social and economic con-
siderations.136–139 
Low- and middle-income countries 
are differentially affected by multimor-
bidity, which drastically reduces life ex-
pectancy and increases personal, social 
and economic burden.8,12,140 Not only 
is the prevalence of noncommunicable 
diseases escalating globally, but the risks 
of infectious diseases have not declined 
in low- and middle-income countries, 
further increasing the burden and com-
plexity of managing chronic conditions 
in these countries.141 However, only 50–
67% of low- and middle-income country 
guidelines provided recommendations 
for the assessment and management of 
psychiatric or cardiometabolic comor-
bidities in depression. Future guidelines 
should provide guidance for screening 
and managing multimorbidity in adults 
with depression.
Most guidelines for the manage-
ment of depression provided tools for 
the application of guideline recommen-
dations, such as a summary document 
or a quick-reference guide. However, less 
than one fifth of the guidelines we iden-
tified provided materials for patients; 
fewer targeted policy-makers or pay-
ers. Guideline implementation requires 
diversity in the engagement of target 
audiences and stakeholders, as well as 
realistic and relevant implementation 
plans.142 Future guidelines, therefore, 
need to be developed collaboratively by 
a broader collective of stakeholders.137 
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Guideline development groups 
should include experts in experimental, 
observational and contextual evidence 
and knowledge users (such as clinicians 
and patient advocates).14,137,143,144 How-
ever, less than one third of guidelines for 
depression globally included a multidis-
ciplinary development group; in com-
parison, approximately 64% (36/56) of 
guidelines for diabetes mellitus and 52% 
(12/23) of guidelines for hypertension 
were developed by a multidisciplinary 
authorship group.145,146 Many guidelines 
for depression identified in our study 
were developed without target-user 
representatives or patient advocates who 
would be able to provide guidance on 
the appropriateness, translatability, 
feasibility and acceptability of guideline 
recommendations.
Guidelines endeavour to com-
prehensively review and corroborate 
knowledge of intervention efficacy, 
effectiveness, safety and tolerability. 
Guidelines must also be informed by 
an evaluation of the determinants, pro-
cesses and outcomes of implementing 
evidence-based recommendations.137 
However, while 60% of guidelines for 
the management of depression identified 
herein were based on a systematic review 
of intervention efficacy and effectiveness 
literature, only 25% of guidelines evalu-
ated enablers and barriers to implemen-
tation. Such gaps in the development 
processes of existing guidelines may 
limit the implementation of guidelines 
for mood disorders.147–149 Future guide-
lines for the management of depression 
should involve a combination of inter-
national and local collaboration, taking 
into consideration contextual factors 
that may facilitate or hinder access to 
health services or treatments. Contex-
tual factors that may be relevant include, 
for example, structural or policy aspects 
of the health-care system, education and 
training; access to treatment methods 
for depression; and availability of mod-
ern technology.
The main aim of our initiative was 
not to synthesize a consensual set of im-
plementation measures across low- and 
middle-income countries. However, les-
sons learnt from implementation science 
across other noncommunicable diseases 
could be a starting point for determining 
policy and implementation principles 
for depression management. For ex-
ample, internet access may be needed 
to facilitate guideline dissemination, 
especially in low- and middle-income 
countries. The integration of technol-
ogy may also facilitate chronic disease 
management. The guiding principles 
include prioritizing the involvement of 
stakeholder and end-user input in any 
policy around implementation, identifi-
cation of those people most at risk, and 
appraisal of local health-care resources.
The paucity of depression guide-
lines from low-income countries may 
reflect limitations in our search strategy 
(for example, the African Journals On-
line database primarily includes articles 
published in English). We were more 
likely to identify guidelines available on-
line than in print only. To mitigate this 
possibility, we contacted members of the 
Global Alliance for Chronic Diseases 
and members of national psychiatric or 
other medical associations across geo-
graphical and linguistic world regions. 
Database searches may miss guidelines 
published as government reports or 
in formats other than peer-reviewed 
journal articles or meeting abstracts. To 
improve the likelihood of detecting such 
guidelines, we manually searched the 
websites of multiple national and inter-
national medical associations and min-
istries of health and included experts 
from 27 countries across all continents 
in our collaboration. Thus, the possible 
selection bias in our search is unlikely 
to confound our findings of differences 
in guideline quality and development 
across economic strata. 
Our large number of evaluators 
may have resulted in differences in data 
extraction. However, we completed 
blinded evaluations in duplicate using 
structured evaluation forms; a third 
reviewer independently evaluated all 
forms. In addition, guidelines were eval-
uated by two or three reviewers who had 
not been involved in their development.
The focus of our analysis on guide-
lines may inadequately capture sepa-
rate implementation studies of guide-
lines. Future research should primar-
ily evaluate implementation studies of 
guidelines. We limited our inclusion 
criteria to national and international 
guidelines, which may not capture 
more regional or local differences in 
guideline development or implementa-
tion. Our comparison of guidelines by 
country-level income classification and 
Healthcare Access and Quality index 
did not consider differences in the avail-
ability and accessibility of health care 
within individual countries. Much of the 
available research informing guideline 
recommendations has been conducted 
in high-income countries, with an over-
representation of Caucasian groups, 
often overestimating patient access to 
expensive medications and specialized 
care. 
In conclusion, the implementation 
of guidelines for the management of 
depression is inadequately planned, 
reported and measured. As a result, 
it remains unknown to what extent 
guidelines are acceptable to patients 
and other target users; are feasible and 
cost–effective; and improve health 
outcomes. Narrowing the disparities in 
the development and implementation 
of guidelines, particularly in low- and 
middle-income countries, is a priority. 
Refinement of decision support pro-
cesses in depression is a critical first step 
towards the aim of reducing morbidity, 
especially in low- and middle-income 
countries. Future guidelines should 
present strategies to implement recom-
mendations and measure feasibility, 
cost–effectiveness and impact on health 
outcomes, co-designed by stakeholders 
and experts with practical (experiential) 
knowledge from low- and middle-
income countries. ■
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ملخص
وضع املبادئ التوجيهية للتعامل مع االكتئاب وتنفيذها: مراجعة منهجية
الرسيرية  للمامرسة  التوجيهية  املبادئ  وضع  عملية  تقييم  الغرض 
للتعامل مع االكتئاب وتنفيذها عىل مستوى العامل.
احلالية  التوجيهية  للمبادئ  منهجية  مراجعة  أجرينا  لقد  الطريقة 
بحاالت  املصابني  البالغني  لدى  االكتئاب  مع  بالتعامل  اخلاصة 
يتعلق  وفيام  القطب.  ثنائي  االضطراب  أو  االكتئايب  االضطراب 
بكل مبدأ توجيهي حمدد، قمنا بتقييم االمتثال ملقاييس جودة وضع 
التوجيهي  املبدأ  وضع  عمليات  يف  (كالشفافية  التوجيهي  املبدأ 
التخصصات،  متعددي  املؤلفني  من  جمموعة  وتكوين  والتمويل، 
وتنفيذها  النسبية)،  الفعالية  ألبحاث  املنهجية  املراجعة  وكذلك 
التوجيهية  املبادئ  بمقارنة  قمنا  كام  اجلودة).  مؤرشات  (مثل 
مع  الدخل،  ومتوسطة  الدخل  منخفضة  البلدان  يف  املوجودة 
مثيالهتا املوجودة يف البلدان مرتفعة الدخل.
توجيهًيا  مبدًأ  و13  وطنًيا،  توجيهًيا  مبدًأ   82 حددنا  لقد  النتائج 
 83 دولًيا من املبادئ التوجيهية اخلاصة باملامرسات الرسيرية، من 
التوجيهي،  املبدأ  وضع  عمليات  حتديد  تم  ولقد  لغة.   27 بـ  بلًدا 
املبادئ  من  أصغر  نسبة  يف  واضح  بشكل  التمويل  ومصادر 
التوجيهية، الواردة من البلدان منخفضة الدخل ومتوسطة الدخل 
(58/35؛  الدخل  مرتفعة  بالبلدان  مقارنة   ،(28% (29/8؛ 
%60). وتم وضع عدد أقل من املبادئ التوجيهية (29/2؛ 7%) 
بواسطة  الدخل،  ومتوسطة  الدخل  منخفضة  البلدان  من  الواردة 
بالبلدان  مقارنة  التخصصات،  متعددة  التطوير  جمموعات  إحدى 
مرتفعة الدخل (58/22؛ %38). وقد تم إجراء مراجعة منهجية 
للبلدان  التوجيهية  املبادئ  (29/9) من   31% النسبية يف  للفعالية 
من   (58/41)  71% مقابل  الدخل،  ومتوسطة  الدخل  منخفضة 
وصف  يتم  ومل  املرتفع.  الدخل  ذات  للبلدان  التوجيهية  املبادئ 
خطط لتقييم مؤرشات اجلودة أو االلتزام بالتوصيات إال يف 10% 
البلدان منخفضة  (29/3) الواردة من  املبادئ التوجيهية فقط  من 
املبادئ  من   (58/11) فقط  و19%  الدخل،  ومتوسطة  الدخل 
التوجيهية للبلدان عالية الدخل.
االستنتاج مل يتم التخطيط لعملية تنفيذ املبدأ التوجيهي، واإلبالغ 
عنها وتقييمها، بشكل مناسب عىل الصعيد العاملي. إذ يعد تضييق 
البلدان  يف  وتنفيذها  التوجيهية  املبادئ  وضع  عملية  يف  الفوارق 
منخفضة الدخل ومتوسطة الدخل، إحدى األولويات. وجيب أن 
تقدم املبادئ التوجيهية املستقبلية إسرتاتيجيات لتنفيذ التوصيات، 
وقياس اجلدوى، وفعالية التكلفة، والتأثري عىل النتائج الصحية. 
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结果 我们最终确定了 82 份国家级和 13 份国际级的临
床实践指南，涉及 83 个国家 27 种语言。与高收入国
家相比，中低收入国家指南中明确说明其制定过程和
资金来源的比例略低，29 份中仅 8 份给予明确说明，
占比 28%，而高收入国家则达 60%，58 份中有 35 份。
中低收入国家由多学科编撰成员编著的指南（29 份中
仅有 2 份，占比 7%）相较于高收入国家也较少（58 
份中有 22 份，占比 38%）。中低收入国家的指南中，
有 31% (9/29) 对比较疗效展开系统审查，而高收入国









Développement et mise en œuvre des directives pour la gestion de la dépression: revue systématique
Objectif Évaluer le développement et la mise en œuvre des directives 
de pratique clinique pour la gestion de la dépression dans le monde.
Méthodes Nous avons effectué une revue systématique des directives 
existantes en matière de gestion de la dépression chez les adultes 
souffrant de troubles dépressifs majeurs ou de troubles bipolaires. Pour 
chaque directive identifiée, nous avons vérifié le degré de conformité 
vis-à-vis des mesures de qualité du développement des directives 
(transparence des processus d'élaboration des directives et de leur 
financement, composition multidisciplinaire du groupe d'auteurs, revue 
systématique des études d'efficacité comparative) ainsi que de la mise 
en œuvre (indicateurs de qualité). Nous avons confronté les directives 
des pays à faible et moyen revenu avec celles des pays à haut revenu.
Résultats Nous avons identifié 82 directives de pratique clinique 
nationales et 13 directives de pratique clinique internationales dans 
83 pays et en 27 langues. Les processus d'élaboration des directives 
et les sources de financement étaient explicitement indiquées dans 
une moindre proportion chez les pays à faible et moyen revenu (8/29; 
28%) par rapport aux pays à haut revenu (35/58; 60%). Le nombre de 
directives rédigées par un groupe d'auteurs multidisciplinaire était moins 
élevé dans les pays à faible et moyen revenu (2/29; 7%) que dans les 
pays à haut revenu (22/58; 38%). Une revue systématique de l'efficacité 
comparative a été menée pour 31% (9/29) des directives dans les pays à 
faible et moyen revenu, contre 71% (41/58) des directives dans les pays 
à haut revenu. Seulement 10% (3/29) des directives émises par les pays 
à faible et moyen revenu et 19% (11/58) de celles émises par les pays à 
haut revenu comprenaient un programme d'évaluation des indicateurs 
de qualité ou de l'adhérence aux recommandations.
Conclusion La mise en œuvre des directives est mal planifiée, mal 
analysée et mal mesurée. Réduire les disparités de développement 
et de mise en œuvre des directives dans les pays à faible et moyen 
revenu est une priorité. À l'avenir, ces directives devraient prévoir des 
stratégies d'exécution des recommandations, mais aussi d'évaluation de 
la faisabilité, de la rentabilité et de l'impact sur l'état de santé.
Резюме
Разработка и внедрение рекомендаций по лечению депрессии: систематический обзор
Цель Оценить разработку и внедрение практических клинических 
рекомендаций по лечению депрессии во всем мире.
Методы Авторы выполнили систематический обзор существующих 
клинических рекомендаций по лечению депрессии у взрослых 
с клинической депрессией или биполярным расстройством. 
Всем идентифицированным клиническим рекомендациям была 
дана оценка по соответствию критериям качества разработки 
клинических рекомендаций (таким как прозрачность процессов 
разработки клинических рекомендаций и финансирования, 
мультидисциплинарный состав группы авторов, систематический 
обзор сравнительных исследований эффективности) и 
реализации (например, показатели качества). Авторы сравнили 
клинические рекомендации из стран с низким и средним 
уровнем доходов и из стран с высоким уровнем доходов.
Результаты Было выявлено 82 национальных и 13 международных 
клинических рекомендации из 83 стран на 27 языках. Процессы 
разработки клинических рекомендаций и источники 
финансирования были четко указаны в меньшем количестве 
клинических рекомендаций из стран с низким и средним уровнем 
доходов (8/29; 28%) по сравнению со странами с высоким 
уровнем доходов (35/58; 60%). Меньшее количество клинических 
рекомендаций (2/29; 7%) из стран с низким и средним уровнем 
доходов по сравнению со странами с высоким уровнем 
доходов (22/58; 38%) было разработано мультидисциплинарной 
группой авторов. Систематический обзор сравнительной 
эффективности был выполнен в 31% (9/29) клинических 
рекомендаций из стран с низким и средним уровнем доходов 
по сравнению с 71% (41/58) клинических рекомендаций из стран 
с высоким уровнем доходов. Только в 10% (3/29) клинических 
рекомендаций из стран с низким и средним уровнем доходов 
и в 19% (11/58) клинических рекомендаций из стран с высоким 
уровнем доходов описаны планы по оценке показателей качества 
или приверженности соблюдению рекомендаций.
Вывод В глобальном масштабе при внедрении клинических 
рекомендаций вопросы планирования, отчетности и измерения 
показателей внедрения решаются неадекватно. Приоритетной 
задачей является приближение стандартов разработки и 
внедрения клинических рекомендаций в странах с низким 
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и средним уровнем доходов к таковым в странах с высоким 
уровнем доходов. В будущих клинических рекомендациях должны 
быть представлены стратегии по внедрению рекомендаций и 
оценке их осуществимости, экономической эффективности и 
воздействию на результаты в отношении здоровья.
Resumen
Elaboración e implementación de directrices para el tratamiento de la depresión: una revisión sistemática
Objetivo Evaluar la elaboración e implementación de las directrices 
de práctica clínica para el tratamiento de la depresión a nivel mundial.
Métodos Se realizó una revisión sistemática de las directrices 
existentes para el tratamiento de la depresión en adultos con trastorno 
depresivo mayor o bipolar. Por cada directriz identificada, se evaluó el 
cumplimiento de las medidas de calidad de elaboración de directrices 
(como la transparencia en los procesos de elaboración de directrices 
y su financiamiento, la composición del grupo multidisciplinario de 
autores, la revisión sistemática del estudio de eficacia comparativo) y 
la implementación (como los indicadores de calidad). En este contexto, 
se compararon las directrices de los países de ingresos bajos y medios 
con las de los países de ingresos altos.
Resultados Se identificaron las directrices de práctica clínica a nivel 
nacional (82) y a nivel internacional (13) de 83 países en 27 idiomas. Los 
procesos de elaboración de directrices y las fuentes de financiamiento se 
especificaron de manera explícita en un porcentaje menor de directrices 
de los países de ingresos bajos y medios (8/29; 28 %) en relación con 
las de los países de ingresos altos (35/58; 60 %). Un grupo de desarrollo 
multidisciplinario elaboró menos directrices (2/29; 7 %) para los países 
de ingresos bajos y medios, en relación con las de los países de ingresos 
altos (22/58; 38 %). Además, se realizó una revisión sistemática sobre la 
efectividad comparativa en el 31 % (9/29) de las directrices de los países 
de ingresos bajos y medios, frente al 71 % (41/58) de las directrices de 
los países de ingresos altos. Solo el 10 % (3/29) de las directrices de los 
países de ingresos bajos y medios y el 19 % (11/58) de las directrices 
de los países de ingresos altos describieron planes para evaluar los 
indicadores de calidad o el cumplimiento de las recomendaciones.
Conclusión La implementación de las directrices no se planifica, 
notifica ni evalúa de manera adecuada a nivel mundial. Es prioritario 
reducir las desigualdades en la elaboración y la implementación de las 
directrices en los países de ingresos bajos y medios. Las directrices que 
se elaboren en el futuro deberán presentar estrategias para implementar 
las recomendaciones y evaluar la viabilidad, la rentabilidad y el impacto 
en los resultados sanitarios.
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